Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VU0359595 (ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is <1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 98.00 | |
5 mg | In stock | $ 232.00 | |
10 mg | In stock | $ 339.00 | |
25 mg | In stock | $ 572.00 | |
50 mg | In stock | $ 818.00 | |
100 mg | In stock | $ 1,130.00 |
Description | VU0359595 (ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases. |
In vitro | VU0359595, at concentrations ranging from 5 to 5000 nM, inhibits both the baseline and FCS/IGF-1 stimulated proliferation of astroglial cells. At doses of 5, 50, and 500 nM, with a 30-min exposure, it does not impact the basal phospholipase D (PLD) activity in astrocytes; however, it significantly reduces mitogen-stimulated PLD activity in a concentration-dependent manner[2]. Additionally, at a concentration of 0.15 μM administered 1 h before and during a 4 h high glucose treatment, VU0359595 notably decreases the high glucose-induced increase in [3H]-phosphatidylethanol (PEth) generation in retinal pigment epithelium (RPE) cells[3]. When applied at 5 μM one hour before lipopolysaccharide (LPS) treatment, it modulates autophagy in LPS-induced RPE cells undergoing a 24-h treatment with 10 μg/ml of LPS[4]. Furthermore, a 2 nM pre-exposure for 30 min effectively blocks the gliotoxin (50 ng/ml)-enhanced internalization of A. fumigatus in A549 cells[5]. |
Synonyms | VU0359595-1, CID-53361951, ML-270 |
Molecular Weight | 497.43 |
Formula | C25H29BrN4O2 |
CAS No. | 1246303-14-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5 mg/mL (10.1 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VU0359595 1246303-14-9 Metabolism Phospholipase VU0359595-1 CID-53361951 ML270 ML 270 VU-0359595 CID 53361951 CID53361951 VU 0359595 ML-270 inhibitor inhibit